In vivo antitumor studies demonstrated the superior antitumor effect of RDCM, which facilitated the maturation of dendritic cells, inhibited the activity of IDO, and increased the proportion of tumor-infiltrating CTLs in CT26 tumor-bearing mice. Here, IDO1 is linked to neoplasm.